| Methods |
2‐week washout; 2‐ to 4‐week single‐blind placebo run‐in; inclusion criteria= mean sitting DBP 95‐115 mm Hg after run‐in; 8‐week double‐blind treatment |
| Participants |
Valsartan 20 mg: n=140(93 males,47 females); mean age=53.8 years; baseline sitting SBP=151.6 mm Hg, DBP=100.8 mm Hg;
Valsartan 80 mg: n=150(88 males,62 females); mean age=53.6 years; baseline sitting SBP=152.1 mm Hg, DBP=100.9 mm Hg;
Valsartan 160 mg: n=148(94 males,54 females); mean age=52.0 years; baseline sitting SBP=149.9 mm Hg, DBP=101.4 mm Hg;
Valsartan 320 mg: n=150(95 males,55 females); mean age=53.7 years; baseline sitting SBP=151.0 mm Hg, DBP=101.3 mm Hg;
Placebo: n=148(98 males,50 females); mean age=53.6 years; baseline sitting SBP=152.4 mm Hg, DBP=100.8 mm Hg |
| Interventions |
Valsartan 20 mg once daily;
Valsartan 80 mg once daily;
Valsartan 160 mg once daily;
Valsartan 320 mg once daily;
Placebo;
taken in the morning |
| Outcomes |
Least squares mean change from baseline in trough sitting SBP/DBP using mercury sphygmomanometer;
WDAE |
| Notes |
BP change reported, SD of change not reported, endpoint BP and SD not reported, baseline SD not reported; imputed overall trial mean SBP/DBP SD of change; BP data from text, p. 801; Jadad score=4; funding source= Ciba‐Geigy |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment? |
Unclear risk |
B ‐ Unclear |
